Bristol Myers Squibb's Admilparant Meets Phase 3 Primary Endpoint in Idiopathic Pulmonary Fibrosis Trial

Bristol Myers Squibb (NYSE: BMY) announced that its drug admilparant met the primary endpoint in the Phase 3 ALOFT-IPF trial for idiopathic pulmonary fibrosis, showing a statistically significant improvement in forced vital capacity (FVC) at the 60 mg dose compared to placebo. The drug also exhibited a favorable safety and tolerability profile, with low discontinuation rates due to adverse events. The company plans to conduct a comprehensive evaluation of the trial data and engage with health authorities for regulatory submissions, while results from an ongoing trial in progressive pulmonary fibrosis are expected in early 2027.